Rocket Pharmaceuticals, Inc. SEC filings RCKT
Rocket Pharmaceuticals, Inc. has 968 filings in SEC EDGAR's recent list, going back to Feb 25, 2004. Its latest annual report, Form ARS, was filed on Apr 6, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 10, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 6, 2026 (material agreement, new debt, unregistered share sale, regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | Apr 6, 2026 | — |
| DEF 14A | Proxy statement | Apr 6, 2026 | May 20, 2026 |
| PRE 14A | Preliminary proxy statement | Mar 25, 2026 | May 20, 2026 |
| DEFA14A | Additional proxy material | Apr 30, 2025 | — |
| DEF 14A | Proxy statement | Apr 30, 2025 | Jun 18, 2025 |
| DEFA14A | Additional proxy material | Apr 29, 2024 | — |
| DEF 14A | Proxy statement | Apr 29, 2024 | Jun 13, 2024 |
| PRE 14A | Preliminary proxy statement | Apr 17, 2024 | Jun 13, 2024 |
| DEFA14A | Additional proxy material | Apr 28, 2023 | — |
| DEF 14A | Proxy statement | Apr 28, 2023 | — |
| DEFA14A | Additional proxy material | Apr 29, 2022 | — |
| DEF 14A | Proxy statement | Apr 29, 2022 | Jun 13, 2022 |
| DEFA14A | Additional proxy material | Apr 30, 2021 | — |
| DEF 14A | Proxy statement | Apr 30, 2021 | Jun 14, 2021 |
| DEFA14A | Additional proxy material | Apr 24, 2020 | — |
| DEF 14A | Proxy statement | Apr 24, 2020 | Jun 16, 2020 |
| DEFA14A | Additional proxy material | Apr 30, 2019 | — |
| DEF 14A | Proxy statement | Apr 30, 2019 | Jun 17, 2019 |
| DEF 14A | Proxy statement | Apr 30, 2018 | Jun 25, 2018 |
| PRE 14A | Preliminary proxy statement | Apr 13, 2018 | Jun 25, 2018 |
| DEFA14A | Additional proxy material | Dec 22, 2017 | — |
| DEFM14A | Filing | Dec 4, 2017 | — |
| DEFA14A | Additional proxy material | Oct 12, 2017 | — |
| PREM14A | Filing | Oct 12, 2017 | Oct 12, 2017 |
| DEFA14A | Additional proxy material | Sep 18, 2017 | — |
| DEFA14A | Additional proxy material | Sep 13, 2017 | — |
| DEFA14A | Additional proxy material | Sep 13, 2017 | — |
| DEF 14A | Proxy statement | Apr 26, 2017 | Jun 20, 2017 |
| DEF 14A | Proxy statement | May 6, 2016 | Jun 23, 2016 |
| DEF 14A | Proxy statement | Apr 29, 2015 | Jun 24, 2015 |
Showing 30 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- RCKT (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- New York, NY
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1281895
- Former names
- INOTEK PHARMACEUTICALS CORP (until Dec 22, 2017)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.